JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (5): 1-5.doi: 10.6040/j.issn.1671-7554.0.2016.222

    Next Articles

A recombinant adenovirus fiber knob protein sensitizes ovarian cancer cells to cetuximab therapy

XIAO Junchao1, JIANG Wen2, NAN Hui3, WANG Peirong1   

  1. 1. Department of Pediatrics;
    2. Central Lab, Second Hospital of Shandong University, Jinan 250033, Shandong, China;
    3. Department of Pediatrics, Liaocheng Peoples Hospital, Liaocheng 252002, Shandong, China
  • Received:2016-03-04 Online:2016-05-16 Published:2016-05-16

PDF (PC)

719

Abstract: Objective To investigate whether Ad35K++ could enhance complement dependent cytotoxicity(CDC)triggered by cetuximab to ovarian cancer, and to explore the possible mechanisms. Methods The SK-OV-3 cells were incubated with Ad35K++, followed by cetuximab and normal human serum(NHS)treatment. CD46 expression of SK-OV-3 cells and apoptosis rate were measured with flow cytometry. The cell inhibition rate was detected with MTT array. The expression of Bcl-2 family and activation of caspase-3 were tested with Western blotting. Results CD46 level on the surface of SK-OV-3 cells was dramatically decreased after being incubated with Ad35K++. Ad35K++ sensitized SK-OV-3 cells to CDC triggered by cetuximab in vitro and enhanced complement mediated apoptosis. The expressions of Bax, cleaved-caspase 3, cleaved-PARP were upregulated and the expression of Bcl-2 was down-regulated. Conclusion Ad35K++ could enhance CDC triggered by cetuximab to ovarian cancer via the activation of mitochondria-mediated apoptotic pathway.

Key words: Ovarian cancer, CD46, Cetuximab, Ad35K++

CLC Number: 

  • R737.3
[1] Singh AP, Senapati S, Ponnusamy MP, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer[J]. Lancet Oncol, 2008, 9(11): 1076-1085.
[2] Lin KT, Yeh YM, Chuang CM, et al. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B[J]. Nat Commun, 2015, 6: 5917. doi: 10.1038/ ncomms6917.
[3] Seward SM, Winer I. Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma[J]. Cancer Metastasis Rev, 2015, 34(1): 5-10.
[4] Hsu YF, Ajona D, Corrales L, et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo[J]. Mol Cancer, 2010, 9: 139. doi: 10.1186/1476-4598-9-139.
[5] Wang H, Liu Y, Li ZY, et al. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy[J]. Blood, 2010, 115(3): 592-600.
[6] Luca T, Barresi V, Privitera G, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells[J]. Cell Prolif, 2014, 47(5): 435-447.
[7] Gomes SE, Simoes AE, Pereira DM, et al. miR-143 or miR-145 overexpression increases cetuximab mediated antibody-dependent cellular cytotoxicity in human colon cancer cells[J]. Oncotarget, 2016. doi: 10.18632/oncotarget.7010.[Epub ahead of print]
[8] Galanis E, Atherton PJ, Maurer MJ, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer[J]. Cancer Res, 2015, 75(1): 22-30.
[9] Rogers LM, Veeramani S, Weiner GJ. Complement in monoclonal antibody therapy of cancer[J]. Immunol Res, 2014, 59(1-3): 203-210.
[10] Meyer S, Leusen JH, Boross P. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer[J]. MAbs, 2014, 6(5): 1133-1144.
[11] Jackson SE, Chester JD. Personalised cancer medicine[J]. Int J Cancer, 2015, 137(2): 262-266.
[12] Mamidi S, Cinci M, Hasmann M, et al. Lipoplex mediated silencing of membrane regulators(CD46, CD55 and CD59)enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab[J]. Mol Oncol, 2013, 7(3): 580-594.
[13] Balakrishnan DD, Kumar SG. Higher Caspase-like activity in symptomatic isolates of Blastocystis spp[J]. Parasit Vectors, 2014, 7: 219. doi: 10.1186/1756-3305-7-219.
[14] Besbes S, Mirshahi M, Pocard M, et al. New dimension in therapeutic targeting of bcl-2 family proteins[J]. Oncotarget, 2015, 6(15): 12862-12871.
[1] YUAN Zonghuai, PAN Guangye, CHI Yuemei, AN Chuanguo, ZHANG Yonggang. Causal relationship between low grade serous ovarian cancer and breast cancer analyzed by Mendelian randomization [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 99-107.
[2] HE Jing, YAN Rugen, WU Zhihong, LI Changzhong. Effects of Xiaozheng Yiai decoction on the proliferation and migration of ovarian cancer SKOV3 cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(5): 1-10.
[3] JIAO Guangli, SHI Zixin, CHEN Rong, SONG Yabo, YANG Fei, CUI Shujun. Radiomics of enhanced CT in predicting the response to platinum-based chemotherapy for ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(12): 62-69.
[4] HA Chunfang, LI Ruyue. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123.
[5] WANG Zhengyang, XIA Yan, SHI Kaixuan, TAO Kun, WANG Xiaojie. Effects of Trametinib on PAX8 expression in ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 25-31.
[6] WANG Baojin, ZHAO Xinxin, LI Xia, MA Qian, WANG Xinyue, SUN Yang, SHI Zhongna. miR-203 targeting Survivin to inhibit the proliferation, migration and invasion of ovarian cancer cells [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 23-28.
[7] GUAN Hongwei, LI Juan, SUN Rui, LIU Jie, LI Changzhong. Biological effects of ubenimex on ovarian cancer A2780 cell [J]. Journal of Shandong University (Health Sciences), 2019, 57(12): 46-51.
[8] XUE Ting, WANG Liming, JIAO Jinwen, LI Yong, GUO Ailian, ZHAO Han. siRNA-mediated silencing of RRM2 in the treatment of epithelial ovarian cancer xenograft in nude mice [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 74-79.
[9] YANG Jiaxin, SHEN Keng, WANG Yao. Status and prospect of fertility preservation treatment for gynecologic malignancies [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 1-7.
[10] ZHANG Ying, YANG Jiaxin, CAO Dongyan, YU Mei, SHEN Keng, HUANG Huifang, PAN Lingya, WU Ming, LANG Jinghe, YOU Yan. Prognostic factors for oncology and fertility outcomes of early stage epithelial ovarian cancer patients who accepted fertility-sparing surgery [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 13-17.
[11] HE Pengjuan, YAN Lei, FAN Mingjun, LIU Xiangbin, ZHAO Xingbo. Effects of simvastatin on TGF-β induced epithelial-to-mesenchymal transition in ovarian cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 46-51.
[12] LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 33-38.
[13] ZHAO Lu, JIAO Jun, ZHANG Teng, JIAO Xinlin, CUI Baoxia. Expression of LXRα in ovarian carcinoma and effects of T0901317 on SKOV3 cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 49-53.
[14] ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie. CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 24-29.
[15] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd